De novo strategy of organic semiconducting polymer brushes for NIR-II light-triggered carbon monoxide release to boost deep-tissue cancer phototheranostics.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101152208 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-3155 (Electronic) Linking ISSN: 14773155 NLM ISO Abbreviation: J Nanobiotechnology Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, 2003-
    • Subject Terms:
      Carbon Monoxide*/chemistry ; Polymers*/chemistry ; Theranostic Nanomedicine*/methods; Animals ; Mice ; Female ; Humans ; Infrared Rays ; Cell Line, Tumor ; Photothermal Therapy/methods ; Photoacoustic Techniques/methods ; Mice, Inbred BALB C ; Semiconductors ; Nanoparticles/chemistry ; Phototherapy/methods ; Neoplasms/therapy ; Neoplasms/drug therapy
    • Abstract:
      The integration of photoacoustic imaging (PAI) and photothermal therapy (PTT) within the second near-infrared (NIR-II) window, offering a combination of high-resolution imaging and precise non-invasive thermal ablation, presents an attractive opportunity for cancer treatment. Despite the significant promise, the development of this noninvasive phototheranostic nanomedicines encounters challenges that stem from tumor thermotolerance and limited therapeutic efficacy. In this contribution, we designed an amphiphilic semiconducting polymer brush (SPB) featuring a thermosensitive carbon monoxide (CO) donor (TDF-CO) for NIR-II PAI-assisted gas-augmented deep-tissue tumor PTT. TDF-CO nanoparticles (NPs) exhibited a powerful photothermal conversion efficiency (43.1%) and the capacity to trigger CO release after NIR-II photoirradiation. Notably, the liberated CO not only acts on mitochondria, leading to mitochondrial dysfunction and promoting cellular apoptosis but also hinders the overexpression of heat shock proteins (HSPs), enhancing the tumor's thermosensitivity to PTT. This dual action accelerates cellular thermal ablation, achieving a gas-augmented synergistic therapeutic effect in cancer treatment. Intravenous administration of TDF-CO NPs in 4T1 tumor-bearing mice demonstrated bright PAI signals and remarkable tumor ablation under 1064 nm laser irradiation, underscoring the potential of CO-mediated photothermal/gas synergistic therapy. We envision this tailor-made multifunctional NIR-II light-triggered SPB provides a feasible approach to amplify the performance of PTT for advancing future cancer phototheranostics.
      Competing Interests: Declarations Ethics approval and consent to participate All the mouse experiments were conducted under the guideline of the Animal Centre of Fujian Normal University (Fuzhou, China) and the assays were ratified by the Animal Ethics Committee of Fujian Normal University (20240040). Consent for publication All the authors agree with the publication. Competing interests The authors declare no competing interests. Supporting information Supporting Information is available and includes (1) experimental reagents and instruments, (2) experimental methods, (3) synthetic route, (4) 1H NMR spectra and GPC result, (5) Zeta potentials, (6) calculation of photothermal conversion efficiency, (7) CO release evaluation, (8) quantitative analysis of HSP70 expression, (9) Cell viability, and (10) IC50 fitting curves.
      (© 2024. The Author(s).)
    • References:
      J Nanobiotechnology. 2023 Dec 20;21(1):497. (PMID: 38124097)
      Mater Horiz. 2020 Jun 1;7(6):1474-1494. (PMID: 33777400)
      Nat Commun. 2020 Apr 20;11(1):1857. (PMID: 32312987)
      Adv Mater. 2023 Aug;35(31):e2209799. (PMID: 37276889)
      J Nanobiotechnology. 2021 Jan 6;19(1):9. (PMID: 33407570)
      Adv Mater. 2018 Dec;30(49):e1801964. (PMID: 30066474)
      Biomaterials. 2020 Jul;245:119986. (PMID: 32229331)
      Biomaterials. 2021 Jun;273:120807. (PMID: 33848730)
      Angew Chem Int Ed Engl. 2024 Apr 22;63(17):e202400372. (PMID: 38445354)
      Nat Commun. 2023 Oct 30;14(1):6905. (PMID: 37903795)
      Adv Mater. 2021 Jan;33(4):e2003458. (PMID: 33325584)
      Mol Cancer. 2023 Jun 14;22(1):95. (PMID: 37316830)
      Nat Commun. 2024 Jan 11;15(1):454. (PMID: 38212623)
      Nat Commun. 2023 May 23;14(1):2950. (PMID: 37221157)
      J Nanobiotechnology. 2022 Jan 21;20(1):44. (PMID: 35062957)
      Angew Chem Int Ed Engl. 2022 Jul 25;61(30):e202204604. (PMID: 35543996)
      Biomaterials. 2022 Jan;280:121319. (PMID: 34923313)
      Theranostics. 2019 May 31;9(14):4168-4181. (PMID: 31281539)
      Natl Sci Rev. 2020 Feb 27;7(9):1485-1512. (PMID: 34691545)
      Adv Mater. 2023 Sep;35(35):e2301901. (PMID: 37079477)
      Angew Chem Int Ed Engl. 2022 Apr 11;61(16):e202200025. (PMID: 35170174)
      Angew Chem Int Ed Engl. 2023 May 8;62(20):e202301617. (PMID: 36929068)
      J Nanobiotechnology. 2023 Sep 4;21(1):314. (PMID: 37667389)
      Acc Chem Res. 2023 Jul 4;56(13):1766-1779. (PMID: 37314368)
      Angew Chem Int Ed Engl. 2024 Apr 8;63(15):e202401036. (PMID: 38362791)
      Chem Soc Rev. 2021 Jan 21;50(2):1111-1137. (PMID: 33245316)
      Small Methods. 2024 Aug;8(8):e2301349. (PMID: 38193272)
      Biomaterials. 2023 Nov;302:122313. (PMID: 37672998)
      Adv Mater. 2023 Mar;35(12):e2210179. (PMID: 36630669)
      Adv Mater. 2023 Jul;35(28):e2300048. (PMID: 37016274)
      Adv Mater. 2018 Apr;30(14):e1705980. (PMID: 29457284)
      Theranostics. 2022 Jan 1;12(1):396-409. (PMID: 34987652)
      J Am Chem Soc. 2022 Dec 14;144(49):22562-22573. (PMID: 36445324)
      Small. 2021 Mar;17(12):e2007566. (PMID: 33666345)
      Angew Chem Int Ed Engl. 2021 Oct 4;60(41):22376-22384. (PMID: 34289230)
      Acta Pharm Sin B. 2018 Jul;8(4):587-601. (PMID: 30109183)
      Angew Chem Int Ed Engl. 2023 Jun 12;62(24):e202218768. (PMID: 36890113)
      Nat Commun. 2023 Aug 18;14(1):5017. (PMID: 37596326)
      Adv Mater. 2020 Aug;32(33):e2001146. (PMID: 32627868)
      J Am Chem Soc. 2020 Sep 2;142(35):14789-14804. (PMID: 32786771)
      Chem Soc Rev. 2022 Oct 31;51(21):8957-9008. (PMID: 36226744)
      ACS Nano. 2020 Feb 25;14(2):2509-2521. (PMID: 32022539)
      Adv Mater. 2023 Dec;35(51):e2305287. (PMID: 37547984)
      ACS Nano. 2023 May 23;17(10):8935-8965. (PMID: 37126728)
      Adv Mater. 2023 Aug;35(33):e2303212. (PMID: 37232045)
      J Nanobiotechnology. 2023 Dec 7;21(1):468. (PMID: 38062508)
      Nat Commun. 2022 Aug 5;13(1):4567. (PMID: 35931744)
      Adv Mater. 2024 Jan;36(1):e2304848. (PMID: 37526997)
      Adv Mater. 2024 Apr;36(14):e2310298. (PMID: 38145801)
      Angew Chem Int Ed Engl. 2023 Dec 21;62(52):e202314563. (PMID: 37964723)
      Angew Chem Int Ed Engl. 2022 Dec 12;61(50):e202211674. (PMID: 36184566)
    • Grant Information:
      2023Y9320 Joint Funds for the innovation of science and Technology, Fujian province; 2023Y9320 Joint Funds for the innovation of science and Technology, Fujian province
    • Contributed Indexing:
      Keywords: Carbon monoxide; Organic semiconducting polymer brushes; Photoacoustic imaging; Photothermal therapy; Second near-infrared window
    • Accession Number:
      7U1EE4V452 (Carbon Monoxide)
      0 (Polymers)
    • Publication Date:
      Date Created: 20241115 Date Completed: 20241115 Latest Revision: 20241117
    • Publication Date:
      20241118
    • Accession Number:
      PMC11562092
    • Accession Number:
      10.1186/s12951-024-02984-6
    • Accession Number:
      39543646